Table 5.
Percent change from baseline to week 8 in lipoprotein particle concentrations (nmol/L) as measured by IM methodology
| Difference in median percent change from baseline (95% CI)* | |||
|---|---|---|---|
| Parameter (mg/dL) | Placebo vs anacetrapib alone | Placebo vs atorvastatin alone | Atorvastatin alone vs anacetrapib + atorvastatin |
| Total VLDL | −32.5 (−45.4, −20.3)†,‡ | −38.3 (−54.4, −25.2)† | −14.2 (−22.9, −4.9)†,‡ |
| VLDL large | −35.2 (−56.5, −16.2)†,‡ | −53.1 (−77.7, −31.4)† | −10.3 (−22.7, 1.4) |
| VLDL medium | −37.9 (−54.7, −23.2)†,‡ | −40.7 (−60.2, −22.5)† | −15.1 (−25.3, −5.1)†,‡ |
| VLDL small | −28.4 (−39.2, 219.1)†,‡ | −34.6 (−47.2, −22.5)† | −15.2 (−23.0, −7.5)†,‡ |
| Total IDL | −17.2 (−29.2, −5.1)†,‡ | −40.9 (−55.1, −30.4)† | −13.1 (−21.0, 24.5)†,‡ |
| IDL large | −36.7 (−46.8, −27.7)†,‡ | −39.6 (−49.4, −27.1)† | −19.3 (−25.6, −13.1)†,‡ |
| IDL small | 4.0 (−14.3, −2.6) | −43.1 (−57.9, −27.3)† | −5.3 (−17.5, 7.6) |
| Total LDL | −51.0 (−60.5, −41.3)†,‡ | −49.6 (−59.2, −39.9)† | −15.4 (−22.9, −7.9)†,‡ |
| LDL large 1 | −65.9 (−79.3, −52.6)†,‡ | −45.7 (−61.5, −28.9)† | −37.1 (−48.1, −26.9)†,‡ |
| LDL medium 2a | −71.8 (284.9, −58.7)†,‡ | −43.9 (−58.3, −28.4)† | −39.1 (−48.5, −31.4)†,‡ |
| LDL medium 2b | −66.9 (−80.1, −53.6)†,‡ | −48.0 (−63.3, −33.4) | −33.6 (−43.2, −23.4)†,‡ |
| LDL small 3a | −43.1 (−60.5, −25.3)†,‡ | −50.5 (−66.7, −35.4)† | −6.6 (−22.1, 10.5)† |
| LDL small 3b | 8.0 (−18.5, 39.3) | −47.8 (−65.6, −28.6)† | 40.3 (16.1, 64.9)†,‡ |
| LDL very small 4a | 62.6 (35.0, 89.4)†,‡ | −30.1 (−46.1, −15.1)† | 83.6 (62.6, 108.7)†,‡ |
| LDL very small 4b | 65.8 (48.5, 86.2)†,‡ | −7.4 (−21.4, 7.0) | 76.2 (54.9, 98.2)†,‡ |
CI, confidence interval; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; IM, ion mobility; IQR, interquartile range; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.
Anacetrapib, combined anacetrapib 150- and 300-mg treatment groups; atorvastatin, atorvastatin 20 mg.
Change from baseline data not normally distributed; Hodges-Lehman estimate of median and distribution-free CI presented; median (IQR) presented at baseline and week 8.
Significant between-group difference with false discovery rate less than 5%.
Significant dose-response including placebo and all anacetrapib doses (ie, 10 mg, 40 mg, 150 mg/300 mg).